Palvella Therapeutics, Inc Cash Flow-to-Debt Ratio
Palvella Therapeutics, Inc cash flow-to-debt ratio. Palvella Therapeutics, Inc (PVLA) has a Cash Flow-to-Debt Ratio of -0.35x as of June 2026, meaning its operating cash flow of $-12.85 Million could theoretically repay 0% of its total liabilities ($36.58 Million) in one year. Check cash flow quality index of Palvella Therapeutics, Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Palvella Therapeutics, Inc (2020–2025)
Cash flow-to-debt ratio of Palvella Therapeutics, Inc from 2020 to 2025. Historical debt coverage capacity for Palvella Therapeutics, Inc across 6 annual periods. Also explore Palvella Therapeutics, Inc annual equity growth to track the company's year-over-year net asset growth rate.
Palvella Therapeutics, Inc Cash Flow-to-Debt Ratio by Year (2020–2025)
Palvella Therapeutics, Inc cash flow-to-debt ratio by year from 2020 to 2025. Year-by-year debt coverage analysis for Palvella Therapeutics, Inc. For the full cash flow conversion analysis, see how efficiently does Palvella Therapeutics, Inc generate cash.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.79x | $-25.01 Million | $31.58 Million | ▼ -87.2% |
| 2024 | -0.42x | $-10.84 Million | $25.63 Million | ▲ +64.7% |
| 2023 | -1.20x | $-13.70 Million | $11.43 Million | ▼ -220.8% |
| 2022 | -0.37x | $-14.84 Million | $39.70 Million | ▼ -401.7% |
| 2021 | -0.07x | $-7.66 Million | $102.81 Million | ▲ +88.0% |
| 2020 | -0.62x | $-45.90 Million | $73.98 Million | — |